Tissue inhibitor of metalloproteinase-1 (TIMP1) is an extracellular protein and endogenous regulator of matrix metalloproteinases (MMPs), essential for extracellular matrix homeostasis. In addition to its inhibitory function, TIMP1 binds membrane receptors such as CD63, activating intracellular signaling pathways that support cell survival, migration, and differentiation (1).
In the central nervous system, elevated TIMP1 expression during early postnatal development suggests key roles in neuronal differentiation, survival, and gliogenesis, including the migration of astrocytes and oligodendrocyte precursors. In the healthy adult brain, TIMP1 expression is relatively low and primarily localized to neuronal cell bodies, indicating tightly controlled physiological activity (2).
TIMP1 is strongly induced in response to CNS injury and neurodegenerative conditions, including epilepsy, myelin damage, and Alzheimer’s disease, where it is mainly expressed by reactive astrocytes and contributes to inflammatory pathways and blood–brain barrier regulation (3,4,5).
Clinically, elevated TIMP1 levels in plasma and tumor tissues are associated with poor outcomes in multiple cancers, including prostate, colon, and lung cancer, supporting its utility as a promising biomarker for disease progression and early detection (6).
